Table 1.

The characteristics of the 4 studies after 1st and 2nd screening

Reference	Study	Patient number	COX2 inhibitors	Rate of Outcome (%)	Response (patient number)				Adverse effect patient number
					Complete response	Partial response	Stable disease	Progressive disease
Hamada et al13	case series, retrospective	33	meloxicam 10mg/day	60	1	7	12	13	0
Yang et al11	case report, retrospective	1	celecoxib 200mg/day	100	1	0	0	0	0
Tanaka et al15	case report, retrospective	1	etodolac 200mg/day	100	1	0	0	0	1 (hot flushes)
Wang et al10	case report, retrospective	1	celecoxib 200mg/day	100	1	0	0	0	0

Nishida et al¹² and Hamada et al¹⁴ were excluded from the review because of the possible overlap with Hamada et al study.¹³